# A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors

> **NCT05746897** · PHASE1 · RECRUITING · sponsor: **Hefei TG ImmunoPharma Co., Ltd.** · enrollment: 38 (estimated)

## Conditions studied

- Ovarian Cancer
- Melanoma
- Triple Negative Breast Cancer
- Colorectal Cancer

## Interventions

- **DRUG:** NM1F Injection
- **DRUG:** Pembrolizumab injection

## Key facts

- **NCT ID:** NCT05746897
- **Lead sponsor:** Hefei TG ImmunoPharma Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-13
- **Primary completion:** 2027-09-30
- **Final completion:** 2027-09-30
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2024-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05746897

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05746897, "A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05746897. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*